Paying users zone. Data is covered by 
.
Get 1 month access to Bristol-Myers Squibb Co. for $17.99, or
get full access to entire website for at least 3 months from $49.99.
We accept:
Bristol-Myers Squibb Co. (BMY)
Enterprise Value to EBITDA (EV/EBITDA)
Difficulty: Intermediate
Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Bristol-Myers Squibb Co., EBITDA calculation
USD $ in millions
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
| Item | Description | The company |
|---|---|---|
| EBITDA | To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. | Bristol-Myers Squibb Co.’s EBITDA declined from 2016 to 2017 but then increased from 2017 to 2018 exceeding 2016 level. |
Enterprise Value to EBITDA Ratio, Current
Bristol-Myers Squibb Co., current EV/EBITDA calculation, comparison to benchmarks
| Selected Financial Data (USD $ in millions) | |
| Enterprise value (EV) | |
| Earnings before interest, tax, depreciation and amortization (EBITDA) | |
| Ratio | |
| EV/EBITDA | |
| Benchmarks | |
| EV/EBITDA, Competitors | |
| Abbott Laboratories | |
| AbbVie Inc. | |
| Allergan PLC | |
| Amgen Inc. | |
| Biogen Inc. | |
| Celgene Corp. | |
| Eli Lilly & Co. | |
| Gilead Sciences Inc. | |
| Johnson & Johnson | |
| Merck & Co. Inc. | |
| Pfizer Inc. | |
| Regeneron Pharmaceuticals Inc. | |
| EV/EBITDA, Sector | |
| Pharmaceuticals & Biotechnology | |
| EV/EBITDA, Industry | |
| Health Care | |
Based on: 10-K (filing date: 2019-02-25).
If company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
Bristol-Myers Squibb Co., historical EV/EBITDA calculation, comparison to benchmarks
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
2018 Calculations
3 EV/EBITDA = EV ÷ EBITDA
= ÷ =
| Ratio | Description | The company |
|---|---|---|
| EV/EBITDA | EV/EBITDA is a valuation indicator for the overall company rather than common stock. | Bristol-Myers Squibb Co.’s EV/EBITDA ratio increased from 2016 to 2017 but then declined significantly from 2017 to 2018. |